<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609153</url>
  </required_header>
  <id_info>
    <org_study_id>COMBINE</org_study_id>
    <nct_id>NCT01609153</nct_id>
  </id_info>
  <brief_title>Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy</brief_title>
  <acronym>COMBINE</acronym>
  <official_title>A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients. - COMBINE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to examine whether an antipsychotic combination treatment of olanzapine and
      amisulpride is more effective than olanzapine and amisulpride alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polypharmacy in antipsychotic therapy is an important issue when treating patients with
      schizophrenia. It is not well confirmed that a combination of two antipsychotic drugs lead to
      therapeutic benefit in contrast to monotherapy. However there is a highly frequent practice
      of combining atypical non-clozapine treatment that could be due to potential benefits when
      seeking alternatives to a high rate of non-response in acute phase. Therefore there is a need
      for further trials of sufficient power to address efficacy and safety issues of this regimen.
      Combining two selected atypical drugs in a complementary way may minimize side-effects and
      enhance efficacy. In order to specify these advantages it is intend to examine approaches to
      combination treatment: Amisulpride and olanzapine show complementing receptor binding
      profiles and have shown to have efficacy and good tolerability when administered in
      combination in retrospective studies. The object of this trial is to study whether acutely
      ill patients with combination of amisulpride and olanzapine are more frequently in
      symptomatic remission after 8 weeks than those with olanzapine or amisulpride monotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Whether there is a symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic improvement of schizophrenia after 16 weeks of treatment in comparison to time of inclusion of patient measured py PANSS total score reduction</measure>
    <time_frame>16 weeks.</time_frame>
    <description>To study whether a combination treatment of olanzapine and amisulpride show a PANSS total score reduction from baseline to week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic improvement of schizophrenia from baseline to week 2 up to week 16 measured by PANSS total score reduction.</measure>
    <time_frame>Every 2 weeks up to week 16.</time_frame>
    <description>Whether a combination treatment of olanzapine and amisulpride show a PANSS total score reduction from baseline to every 2 weeks up to week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS total score reduction from baseline to week 2 as a predictor of the change after 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Whether a change of PANSS total score reduction from baseline to week 2 is a predictor of the change after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse drug reactions</measure>
    <time_frame>16 weeks</time_frame>
    <description>Frequency and severity of serious adverse drug reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clinical condition measured by Clinical Global Impression Scale (CGI scale)</measure>
    <time_frame>every 2 weeks from baseline up to week 16</time_frame>
    <description>Whether there is a change of clinical condition measured by Clinical Global Impression Scale (CGI scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the subjective well-being measured by Subjective Wellbeing under Neuroleptics Scale (SWN-K)</measure>
    <time_frame>between week 0, 8, 16</time_frame>
    <description>Whether there is a change of the subjective well-being measured by Subjective Wellbeing under Neuroleptics Scale(SWN-K)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Olanzapine or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine and Amisulpride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Coated tablet 5-20 mg milligram(s) per day for 16 weeks</description>
    <arm_group_label>Amisulpride or Placebo</arm_group_label>
    <arm_group_label>Olanzapine and Amisulpride</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>200-800 mg milligram(s)per day for 16 weeks</description>
    <arm_group_label>Olanzapine and Amisulpride</arm_group_label>
    <arm_group_label>Olanzapine or Placebo</arm_group_label>
    <other_name>Amisulprid Hexal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine and Amisulpride</intervention_name>
    <description>Zyprexa:
Coated tablet 5-20 mg milligram(s) per day for 16 weeks
Amisulpride:
Coated tablet 200-800 mg milligram(s)per day for 16 weeks</description>
    <arm_group_label>Amisulpride or Placebo</arm_group_label>
    <arm_group_label>Olanzapine or Placebo</arm_group_label>
    <other_name>Zyprexa, Amisuprid Hexal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with schizophrenia and schizoaffective disorder according to International
             Classification of Diseases (ICD-10);

          -  age 18-65;

          -  Positive and Negative Symptom Scale Total-Score ≥ 70 and two items of the positive
             symptom subscale ≥4.

          -  voluntary treatment after written informed consent

          -  legal capacity

          -  exclusion of pregnancy by laboratory test (Beta HCG)

        Exclusion Criteria:

          -  participation in other interventional studies with drugs or medical devices

          -  first episode patients

          -  physical disease that might have effects on the conduct or evaluation of the trial

          -  contraindications to medication according to experts information

          -  oversensitivity to active substance or other component of the drugs used

          -  known clozapine resistance

          -  suicidal ideation

          -  pregnancy or lactation

          -  which of pregnancy or absence save contraception

          -  dependency to sponsor or investigator

          -  institutionalization through judicial or regulatory order

          -  oversensitivity to placebo (mannite/aerosil)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schmidt-Kraepelin, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine University, Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheinhessen Fachklinik Alzey</name>
      <address>
        <city>Alzey</city>
        <zip>55232</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhein-Mosel-Fachklinik Andernach</name>
      <address>
        <city>Andernach</city>
        <zip>56626</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirkskliniken Schwaben, Bezirkskrankenhaus Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>89156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite-Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LWL-Klinik Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44281</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LVR-Klinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Seelische Gesundheit Kreiskliniken Darmstadt-Dieburg Standort: Groß-Umstadt</name>
      <address>
        <city>Groß-Umstadt</city>
        <zip>64823</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychotherapie und Psychosomatik am Bezirkskrankehaus Günzburg</name>
      <address>
        <city>Günzburg</city>
        <zip>89312</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LVR-Klinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LVR-Klinik Langenfeld</name>
      <address>
        <city>Langenfeld</city>
        <zip>40764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirksklinikum Regensburg, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>amisulpride</keyword>
  <keyword>olanzapine</keyword>
  <keyword>polypharmacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

